共 37 条
- [21] Changes in plasma IL-6, plasma VEGF and serum YKL-40 levels in patients with rheumatoid arthritis during treatment with anti-TNF-α therapy.ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S378 - S378Knudsen, LSOstergaard, MBaslund, BPetersen, JEjbjerg, BSzkudlarek, MJohansen, JS
- [22] SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, LEADS TO IMPROVEMENTS IN WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDYANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 580 - 580Tanaka, Y.Aletaha, D.Peterson, S.Ganguly, R.Kurrasch, R.Popik, S.Agarwal, P.Li, N.
- [23] Efficacy and Safety of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 StudyARTHRITIS & RHEUMATOLOGY, 2016, 68Aletaha, DanielBingham, Clifton, IIITanaka, YoshiyaAgarwal, PrasheenKurrasch, ReginaTak, Paul-PeterPopik, Sharon
- [24] Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels.AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 667 - 667Shin, B.Ammerman, N. F.Vo, A. A.Zhang, X.Jordan, S. C.Toyoda, M.
- [25] Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid ArthritisARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S568 - S568Genovese, Mark C.Fleischmann, Roy M.Jasson, MartineRadin, Allen R.Hamilton, JenniferHuizinga, Tom W. J.
- [26] EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED GLOBAL PHASE 3 STUDY (SIRROUND-T)INTERNAL MEDICINE JOURNAL, 2017, 47 : 27 - 27Pile, K.Aletaha, D.Tanaka, Y.Agarwal, P.Kurrasch, R.Tak, P.Popik, S.
- [27] A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaBLOOD, 2017, 130Brighton, TimothyHarrison, Simon J.Ghez, DavidWeiss, Brendan M.Kirsch, AndreasMagen, HilaGironella, MercedesOriol, AlbertStreetly, MatthewQin, XiangBandekar, RajeshHu, PeterQi, MingNemat, SepidehGoldschmidt, Hartmut
- [28] Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 TrialARTHRITIS & RHEUMATOLOGY, 2016, 68Tanaka, YoshiyaBingham, Clifton, IIIAletaha, DanielAgarwal, PrasheenPopik, SharonKurrasch, ReginaPeterson, SteveGanguly, RitaHan, ChenglongMcQuarrie, Kelly
- [29] Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnfα Therapy Across Two Global Phase 3 TrialsARTHRITIS & RHEUMATOLOGY, 2016, 68Dasgupta, BidishaWalsh, AliceSweet, KristenPeffer, NancyFranks, CarolMa, KeyingSims, MartinCampbell, KimLoza, Matthew
- [30] Long-Term Safety and Efficacy of Tocilizumab, an Anti- IL-6 Receptor Monoclonal Antibody, in Monotherapy, in Patients with Rheumatoid Arthritis (The STREAM Study): Evidence of Safety and Efficacy in a 5-Year Extension StudyJOURNAL FUR MINERALSTOFFWECHSEL, 2009, 16 (04): : 202 - 202Dejaco, C.Duftner, C.